96835-17-5

Usage

Uses

Used in Flavor and Fragrance Industry:
Ethyl Tetrahydropyran-4-Carboxylate is used as a flavoring and fragrance ingredient for its fruity scent, enhancing the sensory experience of various consumer products.
Used in Pharmaceutical Synthesis:
Ethyl Tetrahydropyran-4-Carboxylate is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new medications.
Used in Agrochemical Synthesis:
Ethyl Tetrahydropyran-4-Carboxylate is utilized as a component in the production of agrochemicals, playing a role in the creation of agricultural products to improve crop yields and protect plants from pests.

InChI:InChI=1/C8H14O3/c1-2-11-8(9)7-3-5-10-6-4-7/h7H,2-6H2,1H3

Upstream product

• 5382-77-4 tetrahydro-pyran-4,4-dicarboxylic acid diethyl ester 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 64-17-5 ethanol 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 

Downstream Products

• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 96835-18-6 Bis-(4-methoxy-phenyl)-(tetrahydro-pyran-4-yl)-methanol 
• 4111-54-0 lithium diisopropyl amide 
• 1010798-64-7 3-oxo-3-(tetrahydro-2H-pyran-4-yl)propanenitrile 
• 101691-65-0 toluene-4-sulfonic acid tetrahydropyran-4-ylmethyl ester 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

Processes for preparing 3-Arylsulfur hydroxamic acids

This invention provides processes for the preparation of a compound of Formula I: Y—C(═O—C(R1)(R2)—CH2—S(O)nR3 wherein: Y is hydroxy or XONX, where each X is independently hydrogen, lower alkyl or lower acyl; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or R1and R2together with the carbon atom to which they are attached form a cycloalkyl or heterocyclo group; R3is aryl; and n is 0, 1 or 2. The invention also provides novel aryl haloalkyl sulfide intermediates useful for the preparation of compounds of Formula I and novel methods of preparing aryl alkyl sulfides.

Matrix metalloprotease inhibitors

The present invention relates to compounds of Formula I: STR1 that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.

Matrix metalloprotease inhibitors

Compounds of the formula: wherein: n is0, 1 or 2; Y ishydroxy or XONH-, where X is hydrogen or lower alkyl; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocylo-lower alkyl, heterocyclo-lower heteroalkyl or -NR6R7, wherein: R6is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R7is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, -C(O)R8, -C(O)NR8R9, -SO2NR8R9, -SO2R10, aryloxycarbonyl, or alkoxycarbonyl; or R6and R7together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein R8and R9are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R10is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R1and R2together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R3ishydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R4ishydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R2and R3together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R3and R4together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R5islower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or pharmaceutically acceptable salts or esters thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.